MNOV

Medicinova Inc

1.41

Oct 21 • 3:59 PM ET +0.05 (3.68%)

1.37

Aftermarket • 7:30 PM ET -0.04 (-2.94%)

Healthcare Biotechnology USA Micro NASD

Peers: COYA CLNN IMUX PMN ANVS ATHE CGTX PLRX AMLX ATRA

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	69.40M
Enterprise Value	44.10M
Income	-10.75M
Sales	0.92M
Book/sh	0.76
Cash/sh	0.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Dec 07, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	75.43
P/B	1.86
P/C	2.73
P/FCF	-
EV/EBITDA	-
EV/Sales	47.93
Quick Ratio	8.75
Current Ratio	8.75
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.22
EPS next Y	-0.45
EPS next Q	-0.06
EPS this Y	-6.25%
EPS next Y	-75.16%
EPS next 5Y	-
EPS past 3/5Y	5.19% 4.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	9.14%
Sales Y/Y TTM	583.87%
EPS Q/Q	29.75%
Sales Q/Q	240.60%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	28.91% 512.00%

Insider Own	5.12%
Insider Trans	-20.25%
Inst Own	18.15%
Inst Trans	-0.58%
ROA	-23.83%
ROE	-25.56%
ROIC	-28.85%
Gross Margin	31.14%
Oper. Margin	-1287.41%
Profit Margin	-1168.20%
SMA20	-16.96%
SMA50	-20.76%
SMA200	-6.93%
Trades

Shs Outstand	49.22M
Shs Float	46.70M
Short Float	0.73%
Short Ratio	1.05
Short Interest	0.34M
52W High	3.90 -63.85%
52W Low	1.17 20.72%
Volatility	5.17% 8.66%
ATR (14)	0.16
RSI (14)	36.89
Beta	0.69
Rel Volume	0.10
Avg Volume	322.56K
Volume	32,603

Perf Week	-4.08%
Perf Month	-51.38%
Perf Quarter	7.63%
Perf Half Y	0.00%
Perf YTD	7.63%
Perf Year	15.57%
Perf 3Y	-30.20%
Perf 5Y	-61.89%
Perf 10Y	-80.03%
Recom	1.00
Target Price	8.25
Prev Close	1.36
Price	1.41
Change %	3.68%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-26	Initiated	Roth Capital	Buy	$6
Mar-16-26	Initiated	H.C. Wainwright	Buy	$10
Mar-10-21	Initiated	Maxim Group	Buy	$15
Mar-25-19	Resumed	B. Riley FBR	Buy	$22
Mar-28-18	Initiated	B. Riley FBR, Inc.	Buy	$22
Apr-18-17	Initiated	Credit Suisse	Outperform
Jan-04-13	Reiterated	Ladenburg Thalmann	Buy	$10.50 → $6
May-24-12	Downgrade	MLV & Co	Buy → Hold
Oct-18-11	Reiterated	MLV Capital	Buy	$13 → $6
Jun-22-11	Initiated	Global Hunter Securities	Buy	$4
May-12-10	Initiated	Wedbush	Outperform	$13
Nov-12-08	Reiterated	Ladenburg Thalmann	Buy	$22 → $6
May-15-08	Initiated	Rodman & Renshaw	Mkt Outperform	$9
Jul-09-07	Initiated	Punk, Ziegel & Co	Buy	$22

Show Previous Ratings

Oct-12-26 06:00AM	MediciNova CEO Provides Shareholder Update (GlobeNewswire)
Oct-06-26 06:00AM	MediciNova to Participate in the Maxim Growth Summit (GlobeNewswire) -5.98%
Sep-28-26 09:58AM	MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints (InvestorsHub) -18.60%
09:20AM	MediciNova stock tumbles on mixed Phase 2 NAFLD trial data (Investing.com)
06:00AM	MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire)
11:23PM	Loading…
Sep-24-26 11:23PM	MRNA On Track To Be September's No. 2 S&P 500 Stock But These 5 Smaller Health Care Names Did Even Better (Stocktwits) -5.36%
06:00AM	MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) (GlobeNewswire)
Sep-08-26 06:00AM	MediciNova to Participate in Two Investor Conferences in September (GlobeNewswire) +7.36%
Aug-13-26 05:46PM	MediciNova: Q2 Earnings Snapshot (Associated Press)
Jul-15-26 08:00AM	MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients (GlobeNewswire)
Jun-30-26 08:00AM	MediciNova CEO Provides Shareholder Update (GlobeNewswire)
Jun-08-26 08:00AM	MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment (GlobeNewswire)
May-26-26 07:00PM	MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire)
May-14-26 06:44PM	MediciNova: Q1 Earnings Snapshot (Associated Press)
Apr-27-26 07:00PM	New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation (GlobeNewswire)
09:44AM	Loading…
Mar-23-26 09:44AM	Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls (The Fly) -7.05%
Mar-16-26 07:00AM	MediciNova to Participate at the 38th Annual ROTH Conference (GlobeNewswire) +7.41%
Feb-20-26 06:40AM	MediciNova: Q4 Earnings Snapshot (Associated Press Finance)
Jan-29-26 06:00PM	MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients (GlobeNewswire)
Jan-06-26 09:00AM	2026 New Year's Greetings from the CEO (GlobeNewswire)
Dec-18-25 06:00AM	MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy (GlobeNewswire)
Dec-08-25 06:00AM	MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND (GlobeNewswire)
Dec-01-25 06:00PM	Message from the CEO to MediciNova Shareholders (GlobeNewswire)
Nov-18-25 06:00AM	MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor (GlobeNewswire)
Nov-12-25 05:22PM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
Nov-06-25 06:00PM	MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards (GlobeNewswire) -7.28%
Nov-04-25 07:00AM	MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire) -5.33%
Oct-31-25 08:55PM	MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis (TipRanks) +39.50% -9.64%
Oct-30-25 07:00PM	MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication (GlobeNewswire)
Oct-06-25 08:00AM	MediciNova to Present at the LD Micro Main Event XIX Investor Conference (GlobeNewswire)
07:13AM	Loading…
Sep-23-25 07:13AM	MediciNova concludes subject enrolment in trial of MN-166 (Clinical Trials Arena)
Sep-22-25 08:00AM	MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) (GlobeNewswire)
Sep-16-25 08:00AM	MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND (GlobeNewswire)
Sep-08-25 09:00AM	MediciNova Provides Shareholder Update on Key Developments (GlobeNewswire)
Sep-03-25 07:00AM	MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 07:00PM	MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial (GlobeNewswire)
Aug-14-25 05:30PM	MediciNova: Q2 Earnings Snapshot (Associated Press Finance)
Jul-31-25 07:30PM	MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million (GlobeNewswire) +7.92%
Jul-24-25 06:00AM	MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials (GlobeNewswire)
Jun-17-25 09:20AM	MediciNova price target lowered to $5 from $6 at B. Riley (TipRanks) -5.26%
May-13-25 04:56PM	MediciNova: Q1 Earnings Snapshot (Associated Press Finance) -6.16%
Apr-14-25 07:00PM	MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 (GlobeNewswire)
Apr-08-25 07:00PM	First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients (GlobeNewswire) +6.01%
Dec-05-24 06:00PM	MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-19-24 09:00AM	MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders (GlobeNewswire) +5.56%
Nov-14-24 06:00PM	MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver (GlobeNewswire) -8.75%
Nov-13-24 05:08PM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance) -12.28%
Nov-11-24 06:00PM	MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis (GlobeNewswire) +49.02%
Oct-23-24 07:00PM	MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) (GlobeNewswire)
Sep-30-24 09:00AM	MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +9.95%
Sep-09-24 07:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND (GlobeNewswire) -9.05%
Sep-03-24 07:00PM	MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting (GlobeNewswire) +10.00% +7.27%
Aug-29-24 07:00PM	MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition (GlobeNewswire) +14.50%
Jun-20-24 06:00AM	MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations (GlobeNewswire)
Jun-05-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer (GlobeNewswire)
Jun-03-24 06:00AM	MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire) +8.09%
May-28-24 06:00AM	MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions (GlobeNewswire)
May-20-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer (GlobeNewswire)
May-14-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome (GlobeNewswire)
May-10-24 08:52AM	MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024 (InvestorPlace)
May-09-24 07:45PM	MediciNova: Q1 Earnings Snapshot (Associated Press Finance) +8.15%
May-07-24 06:00AM	MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) (GlobeNewswire)
Apr-02-24 07:00PM	MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) (GlobeNewswire)
Mar-26-24 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan (GlobeNewswire) +8.09%
Mar-20-24 07:00PM	MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society (GlobeNewswire)
Mar-12-24 06:30AM	MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Jan-17-24 06:00AM	MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China (GlobeNewswire)
Dec-21-23 06:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Dec-06-23 06:00PM	MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe (GlobeNewswire)
Nov-19-23 06:00PM	MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire)
Nov-10-23 09:57AM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
Oct-27-23 01:00AM	MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria (GlobeNewswire)
Oct-10-23 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada (GlobeNewswire)
Oct-04-23 07:00PM	MediciNova Receives Gene Therapy Milestone Payment (GlobeNewswire)
Sep-29-23 09:11AM	MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model (Zacks)
Sep-27-23 07:00PM	MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Aug-21-23 08:00AM	MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury (Zacks)
Aug-17-23 07:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire) -6.63%
Aug-16-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe (GlobeNewswire) +6.93%
Aug-15-23 07:00PM	MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe (GlobeNewswire)
Aug-14-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe (GlobeNewswire)
Aug-10-23 02:12PM	MediciNova: Q2 Earnings Snapshot (AP Finance)
Jul-23-23 09:56AM	With 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investors (Simply Wall St.)
Jun-29-23 06:00AM	MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting (GlobeNewswire)
May-30-23 05:00AM	MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech (Zacks Small Cap Research)
May-14-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe (GlobeNewswire)
May-12-23 07:47PM	MediciNova: Q1 Earnings Snapshot (AP Finance)
Apr-30-23 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada (GlobeNewswire)
Mar-22-23 11:19AM	We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-09-23 06:00PM	MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Feb-27-23 04:57AM	MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled (Zacks Small Cap Research)
Feb-20-23 06:00PM	MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics (GlobeNewswire)
Feb-08-23 06:00PM	MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID (GlobeNewswire)
Jan-30-23 06:00PM	MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder (GlobeNewswire)
Jan-12-23 06:00PM	MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma (GlobeNewswire)
Jan-10-23 10:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada (GlobeNewswire)
Jan-09-23 10:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil (GlobeNewswire)
Jan-05-23 06:00PM	MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast) (GlobeNewswire) +6.22%
Dec-06-22 06:00PM	MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation (GlobeNewswire)
Dec-05-22 06:00PM	MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
3D Investment Partners Pte. Lt	Formerly 10% Owner	Sep 25 '26	Sale	2.70	640,000	1,728,000	4,862,047	Sep 29 05:00 PM

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Ph.D.Dr. Yuichi Iwaki M.D.

M.P.H.Dr. Kazuko Matsuda M.D.

Ph.D.Dr. David H. Crean M.B.A.

CFO & Principal Financial OfficerMr. Jason J. Kruger CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNOV

Medicinova Inc

Upgrade your Finviz experience